Granulocyte-macrophage colony-stimulating factor increases the proportion of circulating dendritic cells after autologous but not after allogeneic hematopoietic stem cell transplantation

Cytotherapy

Volumn 13, Issue 7, 2011, Pages 888-896

  Eksioglu, Erika Adriana ^a   Kielbasa, Johanna ^a   Eisen, Sarah ^a   Reddy, Vijay ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Autologous hematopoietic stem cell transplantation; Dendritic cells; Granulocyte macrophage colony stimulating factor; Immune reconstitution

Indexed keywords

CD16 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; RECIPIENT; STEM CELL MOBILIZATION; T LYMPHOCYTE SUBPOPULATION;

EID: 84860389555     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2011.579956     Document Type: Article

References (35)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-52.
2. Young JW, Merad M, Hart DN. Dendritic cells in transplantation and immune-based therapies. Biol Blood Marrow Transplant. 2007;13:23-32.
3. Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal Malefyt R, et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science. 1999;283:1183-6.
4. Ardavin C, Martinez del Hoyo G, Martin P, Anjuere F, Arias CF, Marin AR, et al. Origin and differentiation of dendritic cells. Trends Immunol. 2001;22:691-700.
5. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991-1045.
6. Reddy V, Iturraspe JA, Tzolas AC, Meier-Kriesche HU, Schold J, Wingard JR. Low dendritic cell count after allogeneic hematopoietic stem cell transplantation predicts relapse, death, and acute graft-versus-host disease. Blood. 2004; 103:4330-5.
7. Dunbar EM, Buzzeo MP, Levine JB, Schold JD, Meier- Kriesche HU, Reddy V. The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease. Haematologica. 2008;93: 1852-8.
8. Waller EK, Rosenthal H, Jones TW, Peel J, Lonial S, Langston A, et al. Larger numbers of CD4 (bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood. 2001;97: 2948-56.
9. Damiani D, Stocchi R, Masolini P, Michelutti A, Sperotto A, Geromin A, et al. Dendritic cell recovery after autologous stem cell transplantation. Bone Marrow Transplant. 2002;30:261-6.
10. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood. 2000;95:2484-90.
11. Everly JJ, Lonial S. Immunomodulatory effects of human recombinant granulocyte-macrophage colony-stimulating factor (rhuGM-CSF): Evidence of antitumour activity. Expert Opin Biol Ther. 2005;5:293-311.
12. Eksioglu EA, Mahmood SS, Chang M, Reddy V. GM-CSF promotes differentiation of human dendritic cells and T lymphocytes toward a predominantly type 1 proinfl ammatory response. Exp Hematol. 2007;35:1163-71.
13. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med. 1999;50:507-29.
14. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5:296-306.
15. Harzstark AL, Small EJ. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge). Expert Opin Biol Ther. 2007;7:1275-80.
16. Gazitt Y, Shaughnessy P, Devore P. Mobilization of dendritic cells and NK cells in non-Hodgkin's lymphoma patients mobilized with different growth factors. J Hematother Stem Cell Res. 2001;10:177-86.
17. Shaughnessy PJ, Bachier C, Lemaistre CF, Akay C, Pollock BH, Gazitt Y. Granulocyte colony-stimulating factor mobilizes more dendritic cell subsets than granulocyte-macrophage colony-stimulating factor with no polarization of dendritic cell subsets in normal donors. Stem Cells. 2006;24: 1789-97.
18. Nemunaitis J, Rosenfeld CS, Ash R, Freedman MH, Deeg HJ, Appelbaum F, et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15:949-54.
19. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colonystimulating factor stimulates potent, specifi c, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90: 3539-43.
20. Wos E, Olencki T, Tuason L, Budd GT, Peereboom D, Sandstrom K, et al. Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma. Cancer. 1996;77:1149-53.
21. Davidson JA, Musk AW, Wood BR, Morey S, Ilton M, Yu LL, et al. Intralesional cytokine therapy in cancer: A pilot study of GM-CSF infusion in mesothelioma. J Immunother (1997). 1998;21:389-98.
22. Reddy V, Winer AG, Eksioglu E, Meier-Kriesche HU, Schold JD, Wingard JR. Interleukin 12 is associated with reduced relapse without increased incidence of graftversus- host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11: 1014-21.
23. O'D oherty U, Peng M, Gezelter S, Swiggard WJ, Betjes M, Bhardwaj N, et al. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology. 1994;82:487-93.
24. Olweus J, BitMansour A, Warnke R, Thompson PA, Carballido J, Picker LJ, et al. Dendritic cell ontogeny: A human dendritic cell lineage of myeloid origin. Proc Natl Acad Sci USA. 1997;94:12551-6.
25. Thomas R, Lipsky PE. Human peripheral blood dendritic cell subsets. Isolation and characterization of precursor and mature antigen-presenting cells. J Immunol. 1994;153: 4016-28.
26. Engleman EG, Fong L. Induction of immunity to tumorassociated antigens following dendritic cell vaccination of cancer patients. Clin Immunol. 2003;106:10-5.
27. Merad M, Sugie T, Engleman EG, Fong L. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood. 2002;99:1676-82.
28. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol. 2003;15:138-47.
29. Reddy V, Hill GR, Pan L, Gerbitz A, Teshima T, Brinson Y, et al. G-CSF modulates cytokine profi le of dendritic cells and decreases acute graft-versus-host disease through effects on the donor rather than the recipient. Transplantation. 2000; 69:691-3.
30. Klangsinsirikul P, Russell NH. Peripheral blood stem cell harvests from G-CSF-stimulated donors contain a skewed Th2 CD4 phenotype and a predominance of type 2 dendritic cells. Exp Hematol. 2002;30:495-501.
31. Devine SM, Brown RA, Mathews V, Trinkaus K, Khoury H, Adkins D, et al. Reduced risk of acute GVHD following mobilization of HLA-identical sibling donors with GM-CSF alone. Bone Marrow Transplant. 2005;36:531-8.
32. Gazitt Y, Akay C, Thomas C, 3rd. No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-Hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GMCSF followed by G-CSF. Stem Cells Dev. 2006;15:269-77.
33. Reddy V, Meier-Kriesche HU, Greene S, Schold JD, Wingard JR. Increased levels of tumor necrosis factor alpha are associated with an increased risk of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:698-705.
34. Volpi I, Perruccio K, Tosti A, Capanni M, Ruggeri L, Posati S, et al. Postgrafting administration of granulocyte colonystimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood. 2001;97:2514-21.
35. Lonial S, Hicks M, Rosenthal H, Langston A, Redei I, Torre C, et al. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colonystimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. Biol Blood Marrow Transplant. 2004;10:848-57.